Navigation Links
3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
Date:7/10/2012

MENLO PARK, Calif., July 10, 2012 /PRNewswire/ -- 3-V Biosciences, Inc., announced today that George Kemble, PhD, Chief Scientific Officer, will present at the upcoming JMP Securities Healthcare Conference at the Peninsula Hotel in New York City.  Dr. Kemble will provide an overview of 3-V, including a discussion of both its lead program targeting the fatty acid synthase (FASN) pathway for the treatment of chronic hepatitis C virus (HCV) infection and the company's discovery platform.  Dr. Kemble's presentation will take place on Friday, July 13 at 12:00pm.

FASN is a cellular enzyme with increased expression following infection with HCV and in several cancers.  First-generation FASN inhibitors have shown preclinical benefits in a variety of viral infections, including HCV, as well as in models of pancreatic, prostatic, breast and colorectal tumors, but their development has been hindered by poor bioavailability and systemic tolerability.  3-V has discovered and is advancing proprietary FASN inhibitors with pharmaceutical properties that overcome the shortcomings of earlier generations of inhibitors, and have the potential to become potent therapeutics for chronic HCV and other indications.

About 3-V Biosciences

3-V Biosciences, Inc. is a privately held biopharmaceutical company that discovers and develops antiviral therapeutics designed to have broad-spectrum activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance.  The 3-V team applies an integrated approach with internal expertise in virology, biology, drug discovery and development to drive programs forward.  The company is located in Menlo Park, California.

For additional information on 3-V Biosciences, please visit www.3vbio.com.

Contact information Stephen R. Brady Chief Business Officer 650-561-8600


'/>"/>
SOURCE 3-V Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
2. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
3. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
7. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
8. Insmed To Present At JMP Securities 7th Annual Healthcare Conference
9. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
10. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
11. Delcath To Present At JMP Securities Healthcare Conference On July 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... CITY, Calif. , Jan. 19, 2017  Abaxis, ... company manufacturing point-of-care blood analysis instruments and consumables for ... conference call to discuss its financial results for the ... The call will be at 4:15 p.m. ET on ... results for the third quarter fiscal year 2017 after ...
(Date:1/19/2017)... CLEVELAND , Jan. 19, 2017 ViewRay, ... (DFG), a federal institution supporting research in ... installation and patient treatments at the University Clinic Heidelberg ... The MRIdian Linac program will be headed ... who also heads radiation oncology at the German Cancer ...
(Date:1/19/2017)... Pfizer joins Astex, AstraZeneca, ... Consortium   Major research investment to ...   The Milner Therapeutics Institute today ... a partner to the Milner Therapeutics Consortium. Pfizer has ... transfer of materials between industry and academia and allocation ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... ... Angel”: a heartwarming and earnest tale of faith and believing in the path ... the creation of published author, Marjorie Lund-Fontaine, a former professional violinist, alumnus of The ... of her new book, Marjorie says, “‘The Angel’ was written as a fairytale, but ...
(Date:1/20/2017)... ... ... “Christmas in Suffolk”: a story of love, secrets, and mystery. “Christmas in ... where she works in a daycare and looks for inspiration in the local coffee ... Publishing, Sara Seymour’s new book is an adventure of love and secrets. ...
(Date:1/20/2017)... ... January 20, 2017 , ... “God's Miracle Man: Against All Odds”: ... the creation of published author, Keith C. A. Tucker, son of Minister Delores Pinnock ... Outreach pastured by Reverend Mark Hardy , “While sitting up in bed, I felt ...
(Date:1/19/2017)... ... January 19, 2017 , ... Wells ... facility enhancement of their 503A compounding pharmacy located in Ocala, Florida. , ... physicians and patients throughout the United States for high-quality human anti-aging and ...
(Date:1/19/2017)... ... ... WhoHaha , a digital media company dedicated to creating and delivering female-centric, ... three-part video series that uses humor to highlight ways to improve heart health and ... For Good™ movement, which is designed to inspire all Americans to make small changes ...
Breaking Medicine News(10 mins):